Microbial biofilms and associated planktonic bacteria

Microbial biofilms are structured communities of microorganisms encapsulated within a self-produced matrix of extracellular polymeric substances (EPS), including polysaccharides, proteins, and extracellular DNA (Donlan, 2002, Emerging Infectious Diseases). These communities can form on both biotic surfaces, such as human heart valves or lung tissue, and abiotic surfaces, such as catheters and prosthetic joints, providing a protective environment that enhances survival against environmental stressors (Costerton et al., 1999, Science). Planktonic bacteria are the free-living, individual cells that exist in a fluid environment and are typically the primary targets of traditional antibiotics (Hall-Stoodley et al., 2004, Nature Reviews Microbiology). Biofilms play a critical role in the pathogenesis of chronic infections, as the physical barrier of the matrix and the presence of metabolically dormant "persister" cells render them up to 1,000 times more resistant to antimicrobial therapy and host immune clearance than their planktonic counterparts (Lewis, 2001, Antimicrobial Agents and Chemotherapy). Therapeutic strategies often involve a multi-pronged approach: using enzymes like Dornase alfa to degrade the EPS matrix, quorum sensing inhibitors to disrupt community communication, and high-dose antibiotics to kill the resulting planktonic cells (Flemming et al., 2016, Nature Reviews Microbiology). Because this entry represents a complex biological state and community of organisms rather than a single molecular target like a receptor or enzyme, it is classified as a therapeutic focus rather than a canonical molecular target.

Other names

Biofilm-associated microorganismsSessile and planktonic microbial communitiesBacterial biofilmsMicrobial matsBiofilm-embedded bacteria

Drugs targeting this entity work by disrupting the extracellular polymeric substance (EPS) matrix, inhibiting quorum sensing signaling pathways to prevent biofilm maturation, or increasing the metabolic activity of dormant persister cells to restore antibiotic susceptibility (Flemming et al., 2016, Nature Reviews Microbiology). Traditional antibiotics primarily target the planktonic cells by inhibiting cell wall synthesis, protein synthesis, or DNA replication, while specialized anti-biofilm agents focus on promoting dispersal or physical degradation of the protective community structure to expose the microbes to the immune system and standard therapies (Hall-Stoodley et al., 2004, Nature Reviews Microbiology).